Welcome to our dedicated page for Varonis Sys SEC filings (Ticker: VRNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Varonis Systems monetises its patented data-security platform can feel like decoding its own anomaly-detection engine. Subscription conversions, annual recurring revenue and insider option exercises hide deep inside the company鈥檚 10-K, 10-Q and Form 4 stream鈥攅xactly where most investors get lost.
Stock Titan surfaces the signal. Our AI reads every Varonis Systems quarterly earnings report 10-Q filing, flags changes in ARR or cloud-migration costs, and delivers plain-English answers for anyone understanding Varonis Systems SEC documents with AI. Need real-time alerts? We post Varonis Systems Form 4 insider transactions real-time so you can monitor Varonis Systems executive stock transactions Form 4 minutes after they hit EDGAR.
Looking for a single place to review every disclosure type? You鈥檒l find:
- Varonis Systems annual report 10-K simplified with AI-driven highlights of R&D spend and cybersecurity risk factors.
- Varonis Systems proxy statement executive compensation decoded to show how performance stock units align with ARR goals.
- Varonis Systems 8-K material events explained, from acquisitions of cloud-security startups to leadership changes.
- Continuous log of Varonis Systems insider trading Form 4 transactions paired with market-moving 8-K notices.
Whether you鈥檙e seeking a quick Varonis Systems earnings report filing analysis or want Varonis Systems SEC filings explained simply, Stock Titan delivers AI-powered summaries, redline comparisons and key-metric dashboards鈥攁ll updated the moment EDGAR releases them. Spend less time hunting through hundreds of pages and more time deciding if Varonis鈥� next move in zero-trust data security fits your portfolio.
Guy Melamed, Chief Financial Officer and Chief Operating Officer of Varonis Systems, Inc. (VRNS), reported the sale of 10,400 shares of Varonis common stock on 08/22/2025. The shares were sold under a Rule 10b5-1 trading plan adopted in 2024 at a weighted-average price of $59.53 per share, with transaction prices ranging from $59.50 to $59.57. After the sale, Melamed beneficially owned 417,497 shares. The Form 4 was submitted and signed by an attorney-in-fact on 08/26/2025. The filer notes willingness to provide detailed per-price sale data upon request.
Varonis Systems, Inc. (VRNS) notice reports a proposed sale of 100,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $5,852,000 and 112,047,109 shares outstanding. The securities were acquired as restricted stock units on 02/29/2024 and payment/settlement is recorded as N/A. The filer reports no sales in the past three months and includes a representation about absence of undisclosed material adverse information.
Notice of Proposed Sale under Rule 144: This Form 144 reports a proposed sale of 56,940 common shares of Varonis Systems, Inc. (VRNS) with an aggregate market value of $3,332,128.80, using Morgan Stanley Smith Barney LLC as broker and an approximate sale date of 08/22/2025. The shares were acquired as Performance Stock Units on 02/29/2024. The filing shows 112,047,109 shares outstanding. The record also lists two 10b5-1 sales by Guy Melamed within the past three months: 42,705 shares sold on 08/13/2025 for $2,465,133.31 and 51,889 shares sold on 08/01/2025 for $2,859,281.08. The filer attests to Rule 10b5-1 representations and confirms no undisclosed material adverse information.
Insider sale by Varonis CFO/COO under 10b5-1 plan. Guy Melamed, who serves as Chief Financial Officer and Chief Operating Officer, reported a sale of 42,705 shares of Varonis Systems, Inc. (VRNS) on 08/13/2025 at a weighted average price of $57.72 per share. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted in 2024. After this transaction, Melamed beneficially owned 427,897 shares. The Form 4 was signed by an attorney-in-fact on behalf of Melamed and was filed as an individual report.
Varonis Systems filed a Form 144 notifying a proposed sale of 42,705 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $2,427,352.20. The filing lists 112,047,109 shares outstanding and an approximate sale date of 08/13/2025.
The securities were acquired as Restricted Stock Units on 02/29/2024. The notice also records a prior 10b5-1 sale for Guy Melamed of 51,889 shares on 08/01/2025 with gross proceeds of $2,859,281.08. The filing includes the standard seller representation regarding undisclosed material information and references Rule 10b5-1 plan considerations.
Varonis Systems (VRNS) Form 4 鈥� Insider Transaction
Chief Financial & Operating Officer Guy Melamed sold 51,889 common shares on 08/01/2025 under a pre-arranged Rule 10b5-1 plan. The shares were disposed at a weighted-average price of $55.10 (range $55.01鈥�$55.24), generating proceeds of roughly $2.9 million. Following the sale, Melamed鈥檚 direct ownership stands at 470,602 shares.
No derivative securities were involved and no acquisitions were reported. The filing signals a reduction of approximately 10% of Melamed鈥檚 prior direct stake, yet he retains a sizeable position. Because the transaction was executed through a 10b5-1 program, it was scheduled in advance and may not reflect current views on VRNS valuation.
FAQ
What is the current stock price of Varonis Sys (VRNS)?
What is the market cap of Varonis Sys (VRNS)?
